Skip to main content
OpenTrials
Completed

NCT Number: NCT03803228

Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders

During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–41 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Polyclinique Jean Villar, Bruges, France

Loading trial locations.

About this study

Ovarian stimulation is an essential prerequisite for any in vitro fertilization attempt (IVF) to optimize the chances of delivery per cycle. These depend in the first place on the age of the patients and secondly on the number of oocytes collected. There is a strong correlation between these two factors, the ovarian reserve diminishing with age. In older patients or patients with decreased reserve, however, the number of oocytes collected remains a prognostic factor for the chances of delivery.

At the present time, there is no validated intervention that would bring a significant interest on the number of oocytes obtained in the group of bad responder patients. However, it is a very heterogeneous population whose definition has been proposed only recently, the Bologna criteria and questioned by a new proposal from the Poseidon group. The latter is more focused on the prognosis of success, differentiating patients with a diminished reserve (count of antral follicles CFA <5 and / or AMH <1.2 ng / ml) from those with an "unexpected" bad response. As the profiles are better defined, it is easier to determine the impact of a strategy in a specific group.

Recent clarifications on the ovarian cycle and folliculogenesis have shown that several waves of follicular development coexist on the same cycle and that it is perfectly possible to obtain a follicular development with a luteal phase equivalent oocyte quality, compared to conventional stimulations performed in the follicular phase. The main constraint of luteal phase stimulation is the lack of possibility of fresh transfer due to non-synchronization with the endometrium. This constraint is today secondary given the evolution of conservation techniques with the development of embryonic and oocyte vitrification.

On the other hand, there is a differential dependence of FSH follicles, their sensitivity depending on the number of FSH receptors and their duration of exposure to FSH. During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women from 20 to 41 years old
  • CFA <5 and / or AMH <1, 2 ng / ml
  • 19 ≤ BMI ≤ 32
  • Supports IVF or ICSI
  • If antecedent IVF / ICSI, number of oocytes collected <4
  • Attack rank (puncture with transfer) <3
  • Affiliation to the general social security scheme and benefiting from 100% infertility

Exclusion criteria

  • Confirmed ovarian insufficiency (amenorrhea)
  • FSH> 20 IU / l or CFA <1
  • Puncture rank> 3
  • Azoospermia or cryptozoospermia
  • Against indication to ovarian stimulation
  • Presence of a cyst of indeterminate etiology, ovarian, uterine or mammary carcinoma, hypothalamic or pituitary tumors
  • Hypersensitivity to any of the medicines in the protocol
  • Moderate or severe pathology of renal or hepatic function
  • Evolutionary thromboembolic accidents

Treatment and study plan

DUOSTIM

Drug

2 consecutive stimulations by Fertistartkit® on the same cycle

Other names: Same monthly cycle

Conventional stimuli

Drug

2 stimulations by Fertistartkit® performed on 2 different cycles

Other names: Two different menstrual cycles

Primary outcomes

  1. cumulative number of oocytes on 2 punctures

    Time frame: up to 60 days

    cumulative number of oocytes on 2 punctures

Secondary outcomes

  1. cumulative number of follicles> 14mm

    Time frame: up to 60 days

    cumulative number of follicles> 14mm

  2. cumulative number of oocytes in metaphase II

    Time frame: up to 60 days

    cumulative number of oocytes in metaphase II

  3. cumulative number of embryos obtained

    Time frame: 1 month

    cumulative number of embryos obtained

  4. number of embryos transferred

    Time frame: up to 60 days

    number of embryos transferred

  5. number of frozen embryos

    Time frame: 1.5 month

    number of frozen embryos

  6. dose of FSH

    Time frame: up to 60 days

    cumulative total dose of FSH

  7. the number of stimulation days

    Time frame: up to 20 days

    the number of stimulation days

  8. estradiol level

    Time frame: up to 20 days

    estradiol level

  9. LH level

    Time frame: up to 20 days

    LH level

  10. progesterone level

    Time frame: up to 20 days

    progesterone level

  11. transfer rate

    Time frame: 3 months

    cancellation or no transfer rate

  12. rates of early pregnancy

    Time frame: up to 9 months

    cumulative rates of early pregnancy (HCG> 100) and ultrasound (6-7SA)

  13. number of beginner pregnancy

    Time frame: up to 9 months

    number of beginner pregnancy in each groups

  14. cumulative cost

    Time frame: up to 9 months

    cumulative cost of 2 attempts including frozen embryo transfers (treatments, consultations, MPA laboratory and monitoring exams)

  15. Side effects

    Time frame: up to 9 months

    reported side effects

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Intercommunal Creteil

Other

Collaborators

  • IBSA Institut Biochimique SA
  • Laboratoires Genévrier

Registry information

Official study title

Comparison of the Cumulative Number of Oocytes Obtained With 2 Controlled Ovarian Hyperstimulations (COH) Within the Same Cycle With FertistartKit® (DUOSTIM) Versus 2 Conventional COH in Poor Ovarian Responders Undergoing IVF. Bistim Study

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jan 14, 2019
Registry last updated
Dec 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.